Use of eidd-1931 or derivative thereof in treatment of enterovirus infection

EP4527390A4Pending Publication Date: 2026-06-17ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
ACADEMY OF MILITARY MEDICAL SCIENCES
Filing Date
2023-05-17
Publication Date
2026-06-17

AI Technical Summary

Technical Problem

Current treatments for enterovirus infections lack specific antiviral drugs, relying mainly on symptomatic and supportive therapies, which are inadequate for managing diverse and potentially severe symptoms caused by enteroviruses such as hand-foot-and-mouth disease, aseptic meningitis, and myocarditis.

Method used

The compound represented by Formula I, its geometric isomers, pharmaceutically acceptable salts, solvates, and hydrates, are used to inhibit enterovirus replication and are formulated into pharmaceutical compositions for treating enterovirus infections, demonstrating antiviral activity against various enteroviruses, including EV-A71, by inhibiting viral RNA replication and protein production.

Benefits of technology

The compound effectively reduces viral loads and alleviates symptoms in infected cells and animals, showing promise as a specific antiviral treatment for enterovirus infections, improving survival rates and reducing tissue viral loads in vivo.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGAF001_ABST
    Figure IMGAF001_ABST
Patent Text Reader

Abstract

The present invention relates to use of a compound represented by formula I, a geometric isomer thereof or a pharmaceutically acceptable salt, a solvate and / or a hydrate thereof and a pharmaceutical composition comprising the compound in the preparation of a drugs for treating diseases or infections caused by enteroviruses.
Need to check novelty before this filing date? Find Prior Art